Remove Hospital Remove Safety Remove Treatments
article thumbnail

Upadacitinib Now Available for Pediatric Patients with PsA, pJIA

The Dermatology Digest

as a tablet or an oral solution for the treatment of pediatric patients aged 2 and older with active psoriatic arthritis (PsA) as well as polyarticular juvenile idiopathic arthritis (pJIA), provided patients have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, AbbVie reports.

article thumbnail

And the Winners Are…PeDRA Announces 2023 Grant Recipients

The Dermatology Digest

The 2023 PeDRA Research Grant recipients are: Joyce Teng, MD, PhD of Stanford University, will conduct a project titled “ A Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of a Hypertonic Gel in the Treatment of Pediatric Cutaneous Pyogenic Granuloma.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Soterios Pharma’s STS-01 Meets Efficacy Endpoints in AA Trial

The Dermatology Digest

The Company states that STS-01 “builds on a mechanism with a well established safety profile in dermatology, and existing evidence of efficacy in this indication through targeting key relevant cytokines. STS-01 was well tolerated with no major adverse events.

article thumbnail

Sanofi’s OX40-ligand Blocker Produces High Durable Response Rates in AD With Quarterly Dosing

The Dermatology Digest

Sanofi’s investigational OX40-ligand blocker amlitelimab produces sustained improvement in the signs and symptoms of atopic dermatitis (AD) in adults who previously responded and continued treatment and sustained off-drug improvements in those who stopped treatment. of patients withdrawn from treatment, the study showed.

article thumbnail

AD Pipeline Watch: New Research Builds Buzz for Zoryve in AD

The Dermatology Digest

INTEGUMENT-1 and INTEGUMENT-2 (The INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis) were two identical Phase 3, parallel-group, double-blind, vehicle-controlled trials evaluating the safety and efficacy of roflumilast cream 0.15% in AD. Fully 91.5%

article thumbnail

Barzolvolimab Shows Promise in CSU

The Dermatology Digest

The data also showed that a high percentage of patients had complete control of their disease after barzolvolimab treatment. “There is a significant medical need here with very limited approved treatment options available. Secondary endpoints include change from baseline for itch and hives severity scores, and safety.

article thumbnail

Proof of Concept: Oral Heat Shock Protein 90 Inhibitor Shows Promise in HS

The Dermatology Digest

In the parallel-design double-blind trial of 15 HS patients, those patients who received oral RGRN-305, 250 mg, once daily showed a robust treatment response compared with their counterparts who received placebo after 16 weeks of treatment. Treatment-emergent adverse events were not serious and were similar between the two groups.